[Sucecesfull bone marrow transplantation in a case of familial hemophagocytic lymphohistiocytosis type 3].

Trasplante de médula ósea exitoso en un caso de linfohistiocitosis hemofagocítica familiar tipo 3.

Journal

Andes pediatrica : revista Chilena de pediatria
ISSN: 2452-6053
Titre abrégé: Andes Pediatr
Pays: Chile
ID NLM: 101778868

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 16 06 2020
accepted: 07 09 2020
entrez: 9 6 2021
pubmed: 10 6 2021
medline: 26 11 2021
Statut: ppublish

Résumé

Hemophagocytic lymphohistiocytosis (HLH) is an exaggerated activation of the immune system which can be either primary (familial) or secondary. Familial hemophagocytic lymphohistiocytosis type 3 (FHL-3) is a severe immune disorder, caused by mutations in the UNC13D gene, which codes for a protein crucial to the cytotoxic function of lymphocytes. To describe the diagnostic relevance of next-generation sequencing in the approach of a patient with suspected FHL and to demonstrate the effectiveness of bone marrow transplantation as the only curative measure. 4-year-old preschool male, previously healthy, who presented with mononucleosis syndrome and positive IgM for Epstein Barr virus, developing hepatosplenomegaly and progressive clinical de terioration. A lymphoproliferative syndrome was suspected, which was ruled out by bone marrow aspiration, finding evidence of active hemophagocytosis. The patient met the criteria for hemophago cytic syndrome (bone marrow aspiration, pancytopenia, elevated ferritin, and hypertriglyceridemia) and, given the lack of response to first-line management, including antiviral treatment, a possible primary etiology was considered. A molecular study was completed with NGS that was positive for FHL-3. Due to the progressive clinical deterioration, a bone marrow transplantation was performed, presenting successful results after the first year had elapsed. NGS is an indispensable tool in the diagnosis of FHL, mainly when the response to standard treatment is not adequate and facilitates the timely implementation of the necessary therapeutic measures.

Identifiants

pubmed: 34106167
pii: S2452-60532021005000108
doi: 10.32641/andespediatr.v92i2.2696
pii:
doi:

Substances chimiques

Membrane Proteins 0
UNC13D protein, human 0

Types de publication

Case Reports Journal Article

Langues

spa

Sous-ensembles de citation

IM

Pagination

269-273

Auteurs

Gabriela Caicedo-Herrera (G)

Centro de Investigaciones en Anomalías Congénitas y enfermedades Raras, Universidad ICEsI, Cali, Colombia.

Estephania Candelo (E)

Centro de Investigaciones en Anomalías Congénitas y enfermedades Raras, Universidad ICEsI, Cali, Colombia.

Manuela Olaya (M)

Fundación Clínica Valle De Lili, Cali, Colombia.

Paola Pérez (P)

Fundación Clínica Valle De Lili, Cali, Colombia.

Diego Medina (D)

Fundación Clínica Valle De Lili, Cali, Colombia.

Harry Pachajoa (H)

Centro de Investigaciones en Anomalías Congénitas y enfermedades Raras, Universidad ICEsI, Cali, Colombia.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH